Our overarching methodology seeks to integrate the most powerful antitumor strategies to attack cancer from multiple fronts simultaneously and synergistically, with the ultimate objective of curing solid tumors.
Under this guiding methodology, we have established a comprehensive drug innovation system, termed “Precision ADC Design (PAD),” which integrates targeted delivery with multi-mechanism therapeutic strategies to precisely tackle with key challenges for the treatment of solid tumors — tumor heterogeneity, drug resistance, and treatment-related toxicity. This system represents an organic convergence of our in-depth understanding of clinical needs, strong product design capabilities, technological integration and engineering expertise, and robust scientific and translational capabilities.
An Integrated Innovation Engine Built on Two Core Technology Platforms
Our PAD system is driven by an innovation engine with two core capabilities, spanning efficient ADC design and precise target discovery. These capabilities are embodied in our two interconnected technology platforms, which enable a seamless R&D process from target identification to clinical validation.
PAD Molecule Design Platform
This platform serves as the backbone of our R&D technologies, combining our clear understanding of tumor biology and current treatment regimens with our years of experience in ADC drug design. Against our identified therapeutic targets of selected indications, this platform enables rational structure design of ADCs to achieve precise tumor targeting, potent cytotoxic efficacy, and minimized off-target effects.
Published Article: Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023;13(4):950-973. doi:10.1158/2159-8290.CD-22-1368
MabArray Target Discovery Platform
Equipped with an industrialized hybridoma generation system and an ultra-high-density monoclonal antibody library of approximately 100,000 clones, this platform empowers large-scale, high-sensitivity screening of complex cell-surface antigens that are often difficult to capture or characterize using conventional approaches. This platform excels at in-depth analysis of novel tumor therapeutic targets, providing a rich and continuously expandable source of ADC-ready targets across multiple tumor types.
Published Article: An array of 60,000 antibodies for proteome-scale antibody generation and target discovery. Cancer Discov. 2020;6(11):eaax2271. Published 2020 Mar 11. doi:10.1126/sciadv.aax2271